MacroGenics (NASDAQ: MGNX) SVP Peters logs RSU vesting and tax share withholding

Rhea-AI Filing Summary

MacroGenics, Inc. insider activity: Senior VP, General Counsel and Secretary Jeffrey Stuart Peters reported routine equity compensation events. On February 7 and 8, 2026, portions of previously granted restricted stock units vested and were converted into common stock on a one-for-one basis.

On those dates, a total of 6,001 and 8,999 common shares, respectively, were acquired upon RSU conversion at an exercise price of $0. In connection with these vestings, 2,317 and 3,474 shares of common stock were withheld at $1.81 per share to satisfy tax obligations, coded as transaction type “F.”

Following the reported transactions, Peters directly held 22,920 shares of MacroGenics common stock. He also continued to hold derivative positions in restricted stock units from earlier grants, which were originally 18,000 units granted on February 7, 2025 and 27,000 units granted on February 8, 2024, each vesting in three equal annual installments.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Peters Jeffrey Stuart

(Last) (First) (Middle)

9704 MEDICAL CENTER DRIVE

(Street)

ROCKVILLE MD 20850

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MACROGENICS INC [ MGNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Senior VP, GC, and Secretary

3. Date of Earliest Transaction (Month/Day/Year)
02/07/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/07/2026		M		6,001	A	(1)	19,712	D
Common Stock	02/07/2026		F		2,317	D	$1.81	17,395	D
Common Stock	02/08/2026		M		8,999	A	(1)	26,394	D
Common Stock	02/08/2026		F		3,474	D	$1.81	22,920	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	02/07/2026		M			6,001	(2)	(2)	Common Stock	6,001	$0	11,999	D
Restricted Stock Unit	(1)	02/08/2026		M			8,999	(3)	(3)	Common Stock	8,999	$0	9,000	D

Explanation of Responses:

1. Restricted stock units convert into the Company's stock on a one-for-one basis.

2. On February 7, 2025, the reporting person was granted 18,000 restricted stock units, vesting in three equal installments beginning on the first anniversary of the grant date

3. On February 8, 2024, the reporting person was granted 27,000 restricted stock units, vesting in three equal installments beginning on the first anniversary of the grant date.

Remarks:

	/s/ Beth A. Smith, Attorney-in-fact	02/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did MacroGenics (MGNX) report for Jeffrey Stuart Peters?

MacroGenics reported that Senior VP, GC and Secretary Jeffrey Stuart Peters had restricted stock units vest on February 7 and 8, 2026. These RSUs converted into common stock, with some shares withheld to cover taxes, reflecting routine equity compensation activity.

How many MacroGenics shares did Jeffrey Peters acquire through RSU vesting?

Jeffrey Peters acquired 6,001 MacroGenics common shares on February 7, 2026 and 8,999 shares on February 8, 2026 via restricted stock unit conversions. These RSUs converted into common stock on a one-for-one basis, as noted in the filing footnotes.

How many MacroGenics shares were withheld for taxes in this Form 4?

The filing shows 2,317 MacroGenics common shares withheld at $1.81 per share on February 7, 2026 and 3,474 shares withheld at $1.81 per share on February 8, 2026. These “F” code transactions represent shares withheld to satisfy tax obligations from RSU vesting.

What is Jeffrey Peters’ MacroGenics share ownership after these transactions?

After the reported transactions, Jeffrey Peters directly held 22,920 shares of MacroGenics common stock. He also retained derivative holdings in restricted stock units from prior grants, which continue to vest in equal annual installments as described in the footnotes.

What restricted stock unit grants does the MacroGenics Form 4 reference?

The Form 4 notes an 18,000 restricted stock unit grant awarded on February 7, 2025 and a 27,000 unit grant awarded on February 8, 2024. Each grant vests in three equal installments beginning on the first anniversary of its respective grant date.

Who is the insider involved in this MacroGenics Form 4 filing and what is his role?

The insider is Jeffrey Stuart Peters, who serves as Senior Vice President, General Counsel and Secretary of MacroGenics. The filing reports his equity compensation-related transactions, including restricted stock unit vesting and associated share withholding for taxes.